RESUMO
UNLABELLED: Eighty-five percent of children born with IUGR have spontaneous catch-up growth in the first 2 years of life; however, about 10 to 15% do not catch up. Numerous therapeutic trials have demonstrated the efficacy of GH treatment in these children. However, the duration of this treatment is still discussed. OBJECTIVE: The aim of this study was to describe the evolution of growth during and after the end of treatment. POPULATION AND METHODS: This study followed 33 children in our unit, treated with growth hormone under the French indication (3 years of treatment followed by 1 year off treatment) and with a mean follow-up of 3 years after cessation. RESULTS: During the 3 years of therapy, we confirmed an increase in growth velocity that resulted in a mean height above -2 standard deviation score (SDS) in 25 children at 3 years (mean height of 1.4 SDS). Among the 25 children who achieved a height above -2 SDS at three years and therefore stopped treatment, 15 resumed GH due to a secondary catch-down. Among children who didn't catch-up at 3 years, the continuation of GH treatment didn't seem to improve the growth.